Board-Certified Oncology Pharmacists: Their Potential Contribution to Reducing a Shortfall in Oncology Patient Visits

Ignoffo, Robert J.; Knapp, Katherine K.; Barnett, Mitchell J.; Barbour, Sally Y.; D'Amato, Steve; Iacovelli, Lew; Knudsen, Jasen; Koontz, Susannah E.; Mancini, Robert; McBride, Ali; McCauley, Dayna L.; Medina, Patrick J.; O’Bryant, Cindy L.; Scarpace, Sarah L; Stricker, Steve; Trovato, James A.

doi:10.1200/jop.2015.008490

Cited by 40 publications

(56 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Included in these recommen-dations are strengthening the pharmacy workforce by defining minimum standards of pharmaceutical care and utilizing CPAs with physicians [57]. While functioning in these collaborative models, pharmacists can serve as vital extenders of physician providers, helping to close the workforce gap [58][59][60].…”

Section: Humanistic Valuementioning

confidence: 99%

The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group

Clemmons

Alexander²,

DeGregory

et al. 2018

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Pharmacists are increasingly recognized as an essential member of the multidisciplinary team for hematopoietic cell transplant (HCT) patients. However, until recently, their educational background, required training, and potential roles have not been well described. Therefore, the purpose of this manuscript is to provide supporting evidence for the HCT Clinical Pharmacist Role Description, which has been endorsed by several organizations including the American Society for Blood and Marrow Transplantation. This document provides justification for the various roles pharmacists fulfill with respect to medication management, transitions of care, patient and provider education, policy development, quality improvement, and research. Furthermore, evidence supporting the value, financially and otherwise, HCT pharmacists provide is reviewed. Pharmacists in the HCT setting are encouraged to report on novel practice models and potential impact of their services to increase awareness and utilization of HCT pharmacists.

show abstract

Section: Humanistic Valuementioning

confidence: 99%

The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group

Clemmons

Alexander²,

DeGregory

et al. 2018

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

show abstract

“…In 2016 we published an article entitled "Role of the Oncology Pharmacist in Reducing the Shortfall in Oncology Patient Visits" [1] in response to the work of Eriksen and colleagues in 2007 [2,3], who warned that the supply of oncologists would not be able to meet the demand for oncology services by 2020. We showed that oncology-trained pharmacists could have a positive impact on increasing the number patient visits.…”

Section: Introductionmentioning

confidence: 99%

“…Based on the reports of a continuing shortfall in visits, a 2016 study addressed the question of whether OPs could also contribute to increasing available patient visits [1]. The study estimated there would be 3639 OPs with training and/or experience in working clinically with oncology patients by 2020.…”

Section: Introductionmentioning

confidence: 99%

“…The study also estimated the contribution in the form of 30-min oncology patient visits that these pharmacists could make. It was estimated that, at 50% work capacity, OPs could provide 2.6-3.3 million 30-min visits by 2020 and suggested that these pharmacists could help address the shortfall in visits [1]. Furthermore, the contributions and value of OPs were extensively described in a 2019 study by Segal et al which reviewed 66 peer-reviewed studies demonstrating the value and activities of the oncology pharmacist [13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oncology Pharmacists Can Reduce the Projected Shortfall in Cancer Patient Visits: Projections for Years 2020 to 2025

Knapp

Ignoffo

2020

Pharmacy

Self Cite

View full text Add to dashboard Cite

Based on the projected need for a larger oncology care workforce, we estimated the patient care visits and care activities that Board Certified oncology pharmacists (BCOPs) could contribute to oncology care from 2020–2025. Using projected counts for BCOPs through 2025, we estimated that 2.9–4.1 million 30-min BCOP patient visits were possible at 50% workforce capacity. BCOPs’ clinical activities overlapped strongly with those of nurse practitioners (NPs) and physician assistants (PAs) in patient education and treatment management. BCOPs could help reduce provider stress and burnout concerns by spreading these activities across a broader set of providers. BCOPs were more active than NPs and PAs in clinical trials research. Recent advances in immunotherapy, pharmacogenetics, pharmacogenomics, and oral oncolytic agents make the medication-focused training of OPs particularly useful to care teams. Comparison also showed that BCOPs were less active in providing follow-up visits and prescribing. Fulfilling the projected BCOP numbers through 2025 will require continued growth in Postgraduate Year 2 (PGY2) oncology pharmacy resident programs and on-the-job training programs. Our review of the trends in cancer incidence, mortality, and survivorship suggest a sustained need for the activities of BCOPs and other oncology care providers.

show abstract

“…Robert Ignoffo and colleagues 16 used a Delphi panel methodology to examine the potential roles that growing numbers of oncology pharmacy specialists might play in addressing the documented shortage of medical oncologists. The panel agreed upon a number of specific services oncology pharmacists routinely provide, including participating in clinical studies, adjusting chemotherapy and assessing drug response and toxicity, managing adverse drug effects and other patient symptoms (eg, pain management), and several other activities.…”

Section: Current Activities Of and Implications For Pharmacy Educatiomentioning

confidence: 99%

Aligning the AACP Strategic Engagement Agenda with Key Federal Priorities in Health: Report of the 2016-17 Argus Commission

Crabtree

Bootman

Boyle

et al. 2017

American Journal of Pharmaceutical Education

View full text Add to dashboard Cite

EXECUTIVE SUMMARY. The Argus Commission identified three major federal priorities related to health care, including the precision medicine initiative, the Cancer Moonshot and the opioid abuse epidemic. Current activities at the federal level were summarized and an analysis of activities within the profession, and academic pharmacy specifically, was prepared. The implications for pharmacy education, research and practice are compelling in all three areas. Recommendations, suggestions and two policy statements aim to optimize the attention to these priorities by the academy. Further, aligning the AACP Strategic Engagement agenda with the opportunities and threats acknowledged in the analysis is essential.

show abstract

Board-Certified Oncology Pharmacists: Their Potential Contribution to Reducing a Shortfall in Oncology Patient Visits

Abstract: BCOPs can contribute to a projected shortfall in needed patient visits for cancer treatment. BCOPs, along with nurse practitioners and physician assistants could substantially reduce, but likely not eliminate, the shortfall of providers needed for oncology patient visits.

Cited by 40 publications

References 11 publications

The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group

The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group

Oncology Pharmacists Can Reduce the Projected Shortfall in Cancer Patient Visits: Projections for Years 2020 to 2025

Aligning the AACP Strategic Engagement Agenda with Key Federal Priorities in Health: Report of the 2016-17 Argus Commission

Contact Info

Product

Resources

About